Publications by authors named "Laura Lopez-Montero"
Article Synopsis
- Advanced penile squamous cell carcinoma (PSCC) has poor outcomes, and patients often have limited treatment options, but PD-L1 expression is a potential target for immunotherapy, like retifanlimab.
- In the ORPHEUS trial, 18 previously untreated patients received retifanlimab, showing an objective response rate of 16.7% and a median duration of response of 3.3 months, with some patients experiencing clinical benefit.
- The results indicate that retifanlimab has potential activity against advanced PSCC with manageable safety, but the small sample size suggests the need for further studies to confirm these findings.
Purpose: The prognostic and predictive role of trophoblast cell-surface antigen-2 (Trop-2) overexpression in human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer is currently unknown. We retrospectively analyzed Trop-2 expression and its correlation with clinicopathologic features and pathological complete response (pCR) in HER2-positive early breast cancer (EBC) patients treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab in the PHERGain study.
Methods: Trop-2 expression at baseline was determined in formalin-fixed, paraffin-embedded primary tumor biopsies by immunohistochemistry and was first classified into expressing (Trop-2-positive) or not-expressing (Trop-2-negative) tumors.